Program
GT801
A development code. Also written as “GT801 Injection”.
Its studies are mostly in Autoimmune Diseases · Burkitt Lymphoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grit Biotechnology | 22 open or running | early phase 1since Sep 25, 2025 | Sep 25, 2025 | Nov 30, 2027early phase 1 · NCT07205315 |
| Vivacta Biotechnology (Shanghai) | 11 open or running | early phase 1since May 13, 2026 | May 13, 2026 | Dec 30, 2031early phase 1 · NCT07614191 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 25, 2025First study: early phase 1 study in Burkitt LymphomaNew to Grit BiotechnologyGrit Biotechnology · NCT07205315 · 28 planned · China
- Dec 15, 2025Early phase 1 study in Moderate to Severe Refractory Autoimmune DiseaseGrit Biotechnology · NCT07333118 · 22 planned · China
- May 13, 2026Vivacta Biotechnology (Shanghai)'s first study: early phase 1 study in Moderate to Severe Refractory Autoimmune DiseasesNew to Vivacta Biotechnology (Shanghai)Vivacta Biotechnology (Shanghai) · NCT07614191 · 22 planned · China
Ahead
- Nov 30, 2027Primary completion: early phase 1 study in Burkitt LymphomaGrit Biotechnology · NCT07205315
- Mar 31, 2028Primary completion: early phase 1 study in Moderate to Severe Refractory Autoimmune DiseaseGrit Biotechnology · NCT07333118
- Dec 30, 2031Primary completion: early phase 1 study in Moderate to Severe Refractory Autoimmune DiseasesVivacta Biotechnology (Shanghai) · NCT07614191
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07614191Moderate to Severe Refractory Autoimmune Diseases · China | Early 1 | Recruiting | Vivacta Biotechnology (Shanghai) | Dec 30, 2031 | 22 |
| NCT07333118Moderate to Severe Refractory Autoimmune Disease · China | Early 1 | Recruiting | Grit Biotechnology | Mar 31, 2028 | 22 |
| NCT07205315Burkitt Lymphoma · China | Early 1 | Recruiting | Grit Biotechnology | Nov 30, 2027 | 28 |
How it is read
Names in the registry
- “GT801 Injection”, 3 entries
Codes read as this program: GT801.
Conditions, from the studies’ own filings
- Autoimmune Diseases, 2 studies
- Burkitt Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.